IDYA Earnings

IDYA reported its FY2025Q2 earnings on 2025-08-05, showcasing a revenue of 0.00 against an estimate of 4.00M, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.85 by 0% . The stock experienced a -3.52% price change on the earnings day and a -7.6% change over the next five days, reflecting market reactions to the results.

Following IDYA's FY2025Q2 earnings announcement on 2025-08-05, the stock price moved by -3.52% on the day of the release. Over the subsequent five days, it saw a -7.60% change. Historically, IDYA's stock price tends to shift by an average of -4.71% in the 10 days leading up to earnings and +1.00% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate IDYA’s annual revenue to reach 6.00M, while the EPS is projected at -1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Revise Upward by 2.06% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between IDYA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Revise Upward by 2.06% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, IDYA's stock price typically moves by -4.71% in the 10 days before its earnings and +1.00% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -1.00 and revenue of 6.00M.

The earnings call presents a mixed picture. The financials are stable, with a cash runway into 2025, but there's no growth in operating expenses or cash balance. IDE397 shows promising clinical data and safety profile, but reliance on GSK's partnership poses risks. The Q&A reveals no major negative sentiment, but management's lack of clarity on key milestones and GSK's opt-in criteria is concerning. The absence of new partnerships or guidance adjustments further tempers expectations, leading to a neutral outlook on stock price movement.